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INTRODUCTION
Ferroptosis is a type of regulated cell death driven by irondependent lipid peroxidation that can be inhibited by iron chelators and lipophilic antioxidants (Dixon et al., 2012; Stockwell et al., 2017) . The ferroptosis-suppressing cystine/glutamate antiporter system x c is required in some contexts to provide cells with cysteine ); inhibition of system x c can induce ferroptosis through cysteine deprivation (Dixon et al., 2012) , subsequent glutathione (GSH) depletion, and ultimately inactivation of GSH peroxidase 4 (GPX4) Dixon et al., 2014) . However, existing system x c inhibitors, including sulfasalazine, glutamate, sorafenib, and erastin, are not suitable for in vivo evaluation due to the lack of potency, selectivity, and/or metabolic stability. Imidazole ketone erastin (IKE) is an erastin analog with nanomolar potency, high meta-bolic stability, and intermediate water solubility, thus potentially representing a suitable candidate for in vivo evaluation of the impact of ferroptosis driven through system x c inhibition in mouse models of cancer (Larraufie et al., 2015) . Diffuse large B cell lymphoma (DLBCL) is an aggressive malignancy of B lymphocytes, accounting for approximately 30% of all non-Hodgkin's lymphoma cases. DLBCL cell lines are particularly sensitive to system x c inhibition Yang et al., 2014) , due to their inability to use the transsulfuration pathway to synthesize cysteine from methionine (Gout et al., 2001) . DLBCL is a heterogeneous disease, with 60-70% of patients being cured with combination chemotherapy and the remainder succumbing to the disease (Chapuy et al., 2018) . Thus, therapies with distinct mechanisms of action may be beneficial for refractory patients, preventing disease relapse and improving therapeutic outcomes. Here, we identified ferroptosis-sensitive and resistant DLBCL cell lines, and established a subcutaneous DLBCL xenograft model to study the role of ferroptosis in treating DLBCL. We found that IKE exhibits antitumor activity in this DLBCL xenograft model, which correlates with an increase of lipid peroxidation in tumors. These findings suggest that IKE can be effective as a potential therapeutic regimen for DLBCL. While small-molecule system x c inhibitors are promising agents for inducing ferroptosis in cancers that are highly dependent on cystine import (Narang et al., 2007; Guan et al., 2009; Lu et al., 2018) , there are a number of potential concerns in translating such agents to patients. First, many compounds, including some system x c inhibitors, do not accumulate to sufficiently high enough concentrations in target tumor tissues, resulting in a minimal pharmacodynamic effect. Second, while system x c inhibitors are expected to be largely tolerable based on the observation that Slc7a11 knockout mice have no obvious phenotypes (Sato et al., 2005; McCullagh and Featherstone, 2014) , it is possible that systemic inhibition of system x c would cause toxicity in normal tissues, or that off-target effects of system x c inhibitors might cause undesirable toxicities. For these reasons, we hypothesized that improving the formulation and delivery of IKE to tumors might enhance its therapeutic index and potential for translation. For example, nanocarriers could be used to increase tumor targeting through the enhanced permeability and retention (EPR) effect (Yue et al., 2013; Blanco et al., 2015) . Indeed, the polyethylene glycol-poly(lactic-co-glycolic acid) nanoparticle (PEG-PLGA NP) carrier we employed caused increased IKE accumulation in tumors and inhibited tumor growth in mice with less toxicity compared with free IKE. These IKE PEG-PLGA NPs were formulated using a scalable microfluidic NanoAssemblr platform (Gdowski et al., 2018) , with a mean size of $80 nm, polydispersity index of 0.2, surface charge of À17 mV, and loading efficiency of 24% by weight. This formulation could provide a potential therapeutic option and research tool for in vivo studies of DLBCL and other ferroptosis-sensitive cancers.
Several studies have shown the important roles of lipids in ferroptosis Yang et al., 2016; Doll et al., 2017; Kagan et al., 2017; Magtanong et al., 2016) . The significant depletion of polyunsaturated fatty acids (PUFAs) and PUFAcontaining phospholipids has been reported in erastin-treated and erastin-analog-treated HT-1080 cells Yang et al., 2016) . Phosphatidylethanolamines (PEs) containing arachidonyl and adrenoyl have been suggested as preferred substrates in RSL3-induced ferroptosis Doll et al., 2017) . Moreover, some lipid metabolism genes, including acyl-coenzyme A (CoA) synthetase long-chain family member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3 (LPCAT3), have been reported as regulators of ferroptosis Kagan et al., 2017) . In this study, we applied untargeted mass spectrometry (MS) in conjunction with ultra-performance liquid chromatography (UPLC) to profile lipid changes in DLBCL cells and a DLBCL xenograft mouse model in response to IKE treatment. We observed significant changes in 62 lipid species in vitro and 37 lipid species in vivo upon IKE treatment, including phospholipids, triacylglycerides (TAGs), diacylglycerides (DAGs), monoacylglycerides (MAGs), and free fatty acids. In addition, a series of genes encoding lipid metabolism enzymes, including the lipid de novo biosynthetic enzymes acetyl-CoA carboxylase 1 (ACC1) and elongation of very long chain fatty acids protein 7 (ELOVL7); lipid-remodeling enzymes adipose triglyceride lipase (ATGL), secretory phospholipase A2f (sPLA2F), lysophosphatidylethanolamine acyltransferase 1 (LPEAT1), and LPCAT4; and lipid peroxidation enzymes lipoxygenases 12 and 15 (ALOX12 and ALOX15), were upregulated upon IKE treatment. Co-treatment with ferroptosis inhibitors ferrostatin-1 (fer-1) or b-mercaptoethanol (b-Me) in IKE-treated cells prevented the upregulation of these genes, indicating that upregulation comes from system x c inhibition and downstream lipid peroxidation. Collectively, these results suggest the involvement of lipids and lipid metabolism genes in IKE-induced ferroptosis and the protective effect of ferroptosis inhibitors in preventing IKE-induced lipid changes.
RESULTS

IKE Potently Reduces DLBCL Cell Number
The ferroptosis inducer and system x c inhibitor erastin is a useful small molecule for in vitro applications, but it is metabolically labile and has low water solubility and potency, precluding its use in vivo. The small molecule IKE is an erastin analog incorporating a carbonyl ( Figure 1A) that can potentially form a reversible covalent interaction with proteins, resulting in >1003 potency improvement compared with erastin in some cell lines (Larraufie et al., 2015) . Substitution of an ethoxy moiety with isopropoxy resulted in improved metabolic stability, and the imidazole moiety in IKE helped increase water solubility and stability of the ketone, making IKE soluble under acidic conditions. We sought to evaluate DLBCL cell line sensitivity to ferroptosis and to establish a lymphoma xenograft model using a ferroptosis-sensitive DLBCL cell line. A panel of 18 DLBCL cell lines representing distinct DLBCL subtypes, including germinal center B cell-like, activated B cell-like, and unclassified subgroups, was evaluated. The 18 DLBCL cell lines showed differential sensitivity to IKE inhibition, with cell lines exhibiting half-maximal inhibitory concentration (IC 50 ) < 100 nM classified as sensitive cell lines, those with IC 50 > 10 mM classified as resistant cell lines, and those with IC 50 values between 100 nM and 10 mM classified as having intermediate resistance ( Figure 1B) . We further tested the degree of IKE-induced lethality upon co-treatment with the ferroptosis inhibitor fer-1, a radical-trapping antioxidant that inhibits lethal lipid peroxidation during ferroptosis Zilka et al., 2017) . Co-treatment with fer-1 rescued cell death induced by IKE in DLBCL cell lines, indicating that IKEinduced lethality in these cell lines resulted from lipid peroxidation and ferroptosis ( Figure S1A ). Among the sensitive DLBCL cell lines, we selected SUDHL6 for generating a subcutaneous xenograft model in 6-week-old male NCG mice.
IKE Pharmacodynamic Study In Vitro
We aimed to investigate whether IKE specifically inhibited system x c and induced ferroptosis in DLBCL cells. Previous studies found that IKE inhibited glutamate release, and the IKE parental analog erastin inhibited cystine uptake. Thus, we tested the cellular level of reduced GSH, which requires cysteine for its biosynthesis, as a readout of IKE potency. A fluorometric method revealed dose-dependent GSH depletion by IKE ( Figure 1C ); this effect was reversed by co-treatment with 10 mM b-ME, which reduces cystine to cysteine, allowing its import into cells through systems A, ASC, and L, thus circumventing inhibition of system x c -. The IC 50 of GSH depletion by IKE was 34 nM (Figure S1B) in SUDHL6 cells, while sulfasalazine's IC 50 for GSH depletion is in the millimolar range (Narang et al., 2007; Lo et al., 2010) .
We next sought to evaluate whether IKE treatment causes lipid peroxidation, a marker of ferroptosis, in DLBCL cells. Analysis of lipid reactive oxygen species (ROS) by flow cytometry using the lipid peroxidation probe C11-BODIPY revealed a dose-dependent increase in lipid ROS upon IKE treatment in SUDHL6 cells ( Figure 1D ). Co-treatment with 10 mM fer-1 inhibited this signal, as expected ( Figure 1D ). We reasoned that lipo-oxidative stress markers, including lipid-peroxide-product-derived protein modifications might also be used as ferroptosis biomarkers. Malondialdehyde (MDA) is a naturally occurring reactive carbonyl compound that is derived from lipid peroxidation of PUFAs. Immunofluorescence staining with an anti-dihydropyridine-MDA-lysine adduct antibody (mAb 1F83) (Yamada et al., 2001) revealed that dihydropyridine-MDA-lysine adduct abundance was increased upon IKE treatment (Figures S1C and S1D).
To facilitate molecular characterization of ferroptosis induction in DLBCL cells, we analyzed gene expression biomarkers of ferroptosis in these cell lines by qRT-PCR. Expression of genes involved in ferroptosis was analyzed upon IKE treatment. GPX4, cystathionine b-synthase (CBS), and ACSL4 were not upregulated with IKE treatment (data not shown). However, the system x c component SLC7A11,
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(A) The small molecule IKE with isopropoxy, ketone, and imidazole substitutions is more potent than erastin. (B) DLBCL cell line sensitivity was measured by incubating cells with a 2-fold series dilution of IKE (starting from 100 mM) for 24 h followed by a CellTiter-Glo luminescent cell viability test. LY8, DOHH2, SUDHL5, SUDHL2, SUDHL6, SUDHL10, and SUDHL16 were classified as sensitive cell lines (red). HBL1, SUDHL9, WSU-NHL, SUDHL8, RIVA, and KARPAS422 were classified as moderately resistant cell lines (black). SUDHL7, U937, A3/KAW, LY7, and U2932 were classified as resistant cell lines (blue). (C) GSH level was measured with a fluorometric-green probe in SUDHL6 cells treated with different concentrations of IKE with or without 10 mM b-ME for 24 h. (D) Lipid ROS detected with C11-BODIPY fluorescence were measured in SUDHL6 cells treated with different concentrations of IKE with or without 10 mM fer-1 co-treatment. (E) qRT-PCR performed in SUDHL6 cells treated with 500 nM IKE for different lengths of time detected SLC7A11, CHAC1, and PTGS2 mRNA induction compared with DMSO-treated samples. (F) Co-treatment of 10 mM fer-1 with 500 nM IKE for 6 h prevented PTGS2 upregulation, but not SLC7A11 and CHAC1 upregulation, while 10 mM b-ME co-treatment prevented the upregulation of all three mRNAs. Data are plotted as the mean ± SD; n = 2 (B) and (C) or n = 3 (E) and (F) biological replicates. Three independent experiments were performed with similar results for (B) to (F). See also Figure S1 . Cell Chemical Biology 26, 1-11, May 16, 2019 3 prostaglandin-endoperoxide synthase 2 (PTGS2, which encodes cyclooxygenase-2), and ChaC GSH-specific g-glutamylcyclotransferase 1 (CHAC1) expression was significantly increased in SUDHL6 cells following IKE treatment ( Figure 1E ). Compared with the upregulation of PTGS2 and CHAC1, induction of SLC7A11 expression requires a relatively longer-term IKE treatment. PTGS2 was reported to be upregulated by the lipid peroxidation product 4-hydroxy-2-nonenal (Uchida, 2017) and by GPX4 depletion (Sengupta et al., 2013) . Co-treatment with fer-1 inhibited PTGS2 upregulation, suggesting that PTGS2 is a functional biomarker of ferroptosis. Fer-1 co-treatment did not inhibit CHAC1 upregulation, as expected, indicating that CHAC1 is a parallel downstream marker of system x c inhibition not affected by lipid peroxidation ( Figure 1F ). In addition, co-treatment with 10 mM b-ME prevented IKE-induced upregulation of SLC7A11, PTGS2, and CHAC1, suggesting that the upregulation of these genes is downstream of cysteine starvation.
Untargeted Lipidomics of IKE-Treated DLBCL Cells
To investigate the effects of IKE on lipid composition and metabolites, we performed untargeted MS-based lipidomics and gene expression analysis of related enzymes during lipid biosynthesis and oxidation. SUDHL6 cells treated with 1 mM IKE, and 500 nM IKE with or without 10 mM fer-1, 10 mM b-Me, or 10 mM deferoxamine (DFO) co-treatment, were subjected to UPLC-MS analysis. The annotations of the lipid species were determined with Lipostar software (v.1.0.4, Molecular Discovery, UK) (Goracci et al., 2017) . We observed significant (one-way ANOVA, p < 0.05) alterations in the relative abundance of 62 lipid species, including lysophosphatidylcholines (LPCs), phosphatidylcholines (PCs), phosphatidylethanolamines (PEs), and TAGs mainly containing PUFAs, in IKE-treated samples, while co-treatment with b-ME reversed these effects and maintained the levels of these specific lipids to near the amounts on vehicle-treated cells (Figures 2A and 2B ). The decrease in the phospholipids PC and PE upon IKE treatment is consistent with the effects of piperazine-erastin treatment and erastin treatment on lipid composition in HT-1080 cells (Yang et al., 2016; Skouta et al., 2014) . The decrease in TAG lipids upon IKE treatment indicates TAG lipids may be susceptible to oxidation during ferroptosis. Fer-1 cotreatment significantly increased TAG lipids and decreased MAG lipids, suggesting a possible protective role of TAG as a buffer against oxidative damage (Listenberger et al., 2003) . With the induction of oxidants and oxidative stress, lipids can be oxidized via both iron-mediated and enzyme-mediated lipid peroxidation. While co-treatment with DFO inhibited IKEinduced cell death in culture ( Figure S1E ), it only partially eliminated lipidomic changes upon IKE treatment, possibly due to DFO inhibiting iron-mediated lipid peroxidation, but not enzyme-mediated lipid peroxidation, suggesting that only a subset of lipidomic changes are needed for inducing cell death. By measuring the mRNA levels of lipid biosynthesis enzymes upon IKE treatment, we discovered that de novo lipid biosynthesis pathways, phospholipid remodeling pathways, and arachidonic acid oxidation pathways were activated ( Figure 2C ). First, there was significant upregulation of ACC1, which catalyzes the rate-limiting step of fatty acid biosynthesis from acetyl-CoA to malonyl-CoA, and ELOVL7, which catalyzes the rate-limiting reaction of long-chain fatty acid elongation, espe-cially the elongation of C18:3 (n-3) and C18:3 (n-6)-CoAs (Figures 2C and S2) . Second, lipid peroxidation during ferroptosis is a deleterious process, and one way to repair such damage is to remodel lipids, by selectively cleaving the oxidized PUFA tail, replacing it with non-oxidized fatty acids, and subsequently reducing lipid hydroperoxides with GSH peroxidase (Chakraborti, 2003) . The activation of the phospholipid remodeling pathway, including sPLA2, which selectively releases PUFAs at the sn-2 position of phospholipids; ATGL, which hydrolyzes TAGs; and LPCAT4 and LPEAT1, which catalyze the conversion of LPC to PC, and LPE to PE, respectively, is thus important for the oxidative-damage-repair process. Third, in addition to Fenton chemistry-mediated lipid peroxidation, enzyme-mediated lipid peroxidation was also activated in IKE-induced ferroptosis, as there was increased expression of lipoxygenases ALOX12 and ALOX15. Genes upregulated following IKE treatment are highlighted in red in the schematic lipid metabolism overview ( Figure 2D ). The upregulation of these genes was partially reversed by co-treatment of 10 mM fer-1 or 10 mM b-ME ( Figure 2C) , indicating that the observed changes in gene expression result from cysteine depletion and oxidative stress induced by IKE. In summary, these lipidomic changes provide us with a detailed picture of IKE-induced ferroptosis in cell culture at the level of lipid metabolism.
IKE Pharmacokinetics and Pharmacodynamics In Vivo
To determine the suitability of IKE for in vivo studies, we first evaluated multiple dosage routes by administering a single dose of IKE (50 mg/kg, 5% DMSO in Hank's balanced salt solution [HBSS] at pH 4) using intraperitoneal (i.p.), intravenous, and oral routes in non-obese diabetic/ severe combined immunodeficiency (NOD/SCID) mice. Determination of IKE concentration over a period of 8 h revealed i.p. to be the most effective and practical means of IKE administration (Table S1 ). Next, IKE concentration in plasma and tumor samples was determined after a single dose of IKE (50 mg/kg, 5% DMSO in HBSS at pH 4, i.p.) in SUDHL6-xenograft-bearing NCG mice over a period of 24 h. IKE reached the highest plasma concentration of 5.2 mg/mL at 1.35 h, and the highest tumor accumulation of 2.5 mg/mL at 3.30 h ( Figure 3A , Table S2 ).
We collected tumor samples from each time point after a single dose of IKE (50 mg/kg, 5% DMSO in HBSS) and evaluated the abundance of ferroptosis markers. There was significant GSH depletion upon IKE dosing starting from 4 h ( Figure 3B ). The GSH depletion in tumors induced by IKE was persistent at 24 h, even when there was little IKE left in the bulk tumor sample. Consistent with IKE accumulation in the tumor samples, CHAC1, SLC7A11, and PTGS2 mRNAs were upregulated starting at 3 h (3-to 5-fold for PTGS2 and SLC7A11, and 2-fold for CHAC1) ( Figure 3C ). Immunofluorescence analysis of samples at 4 h post-treatment showed that there was increased abundance of a hydropyridine-MDA-lysine adduct and 8-hydroxy-2 0 -deoxyguanosine (8-OHdG), biomarkers for oxidative lesions, indicating that IKE induced lipid peroxidation and more general oxidative stress in these tumor samples ( Figures 3D-3E ).
IKE Untargeted Lipidomic Study In Vivo
We sought to investigate lipidomic changes caused by IKE treatment in vivo. We performed untargeted lipidomics on tumor tissue with a single dose of IKE at different time points. We identified significant (one-way ANOVA, p < 0.05) increases in the relative abundance of free fatty acids, phospholipids, and diacylglycerides (DAGs) upon IKE treatment ( Figures 3F and 3G ). Differences with the cell culture experiment might stem from the different tumor microenvironment in vivo. The lipids identified were enriched in linoleic acid and arachidonic acid metabolism ( Figure S3A ). The significant increase in the levels of DAGs and free fatty acids may result from ATGL-mediated TAG hydrolysis ( Figure S3B ). The increased fatty acids might in turn promote phospholipid remodeling to synthesize specific phospholipids, including PCs and PEs. To explore the free fatty acids effects on cells and ferroptosis, we performed a cell survival test of free fatty acids in the presence or absence of IKE. We found that PUFAs, including g-linolenic acid, eicosapentaenoic acid, and arachidonic acid, were toxic to cells at high concentration (100 mM) ( Figure S3C ). Most free fatty acids (10 mM) sensitized cells to ferroptosis, while oleic acid and palmitoleic acid (10 mM) protected against ferroptosis, which might be due to the fact that these two fatty acids lack bis-allylic sites, which are the sites for lipid peroxidation initiation (Gaschler and Stockwell, 2017) ( Figure S3D ).
IKE PEG-PLGA NPs Have Suitable Properties for
Application In Vivo IKE is soluble under acidic aqueous conditions, but not to the same degree under neutral aqueous conditions ( Figure 1A ). To improve delivery of the compound, we sought to use an NP formulation. We selected biocompatible and biodegradable (C) qRT-PCR performed using RNA extracted from tumor tissue showed that PTGS2, SLC7A11, and CHAC1 mRNA increased starting from 3 h, colored as blue in the heatmap. Data are plotted as the mean, n = 3 individual mice. (D-G) (D and E) Immunofluorescence of dihydropyridine-MDA-lysine adduct in paraffin-embedded tumor samples from mice 4 h after treatment with one dose of vehicle or IKE. Quantification of fluorescence intensity showed 1.6-fold increase of dihydropyridine-MDA-lysine adducts and 1.5-fold increase of 8-OHdG in IKEtreated mouse tumor tissue relative to the vehicle-treated mouse tumor tissue (sections were cut from three mice in each group, five images from each section were captured on Zeiss LSM 800 633/1.40 oil DIC objective). ***p < 0.001, ****p < 0.0001 by t test. Heatmaps of dysregulated lipids in SUDHL6 subcutaneously xenografted NCG mice treated with one dosage of IKE for at 0, 1, 2, 3, 4, 6, and 24 h or with vehicle, detected by untargeted UPLC-MS analysis. Data shown in heatmaps are lipid species that were identified as being statistically significant (p < 0.05) among the groups in (F) negative electrospray ionization mode and (G) positive electrospray ionization mode. Each column represents an independent biological replicate. Each row represents the Z score normalized intensity of a lipid feature. The relative abundance of each identified lipid is color coded in blue, indicating low signal intensity, or red, indicating high signal intensity. Abbreviations: PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; PS, phosphatidylserine, LPC, lysoPC; LPE, lysoPE; FA, free fatty acid; TAG, triacylglyceride; DAG, diacylglyceride, MAG, monoacylglyceride. See also Figure S3 and Table S2. PEG-PLGA di-block copolymer-based NPs as an IKE carrier system ( Figure 4A ). The PEG block was used to create a deformable hydrating layer by tight associations with water molecules, which prevents clearance by the mononuclear phagocyte system, prolonging circulation lifetime. The PLGA block was used to form a hydrophobic core to incorporate IKE, which provides sustained release by diffusion and surface and bulk erosion.
To formulate <100-nm NPs with a reproducible method, we employed the high-flow microfluidic system NanoAssemblr (Gdowski et al., 2018; Valencia et al., 2013) . Self-assembly of NPs by nanoprecipitation occurs when the organic phase containing IKE and the PEG-PLGA polymer combines with the aqueous phase in a microchannel. IKE PEG-PLGA NPs with a diameter as small as 80 nm and polydispersity index of 0.17 were formulated using this approach ( Figure S4) . The surface possessed a slightly negative charge with z potential of À17.0 mV to prevent NP aggregation. One of the problems with the use of NPs as drug carriers in vivo is the low content of drug and low concentration of NPs in suspension. We were able to achieve concentration factors up to 20 using centrifugal filter units without causing NP aggregation or dramatically decreasing IKE loading efficiency ( Figure S4C ). As a result, IKE PEG-PLGA NPs containing IKE as high as 3 mg/mL (drug loading 3.65% by weight and encapsulation efficiency of 24%) were formulated. Compared with free IKE, IKE PEG-PLGA NPs had enhanced cellular activity in SUDHL6 cells ( Figure 4B ), which might result from increased internalization of IKE NPs into the cells. Co-treatment with fer-1 rescued cell death induced by IKE and IKE PEG-PLGA NPs ( Figure S4G ). In addition, administration of 750 mg/kg naked PEG-PLGA NPs daily for 2 weeks did not result in any detectable weight loss or other observable signs of toxicity, suggesting that this NP system was suitable for in vivo drug delivery.
IKE Inhibits Tumor Growth In Vivo and the PEG-PLGA NP Formulation Enhances Its Therapeutic Index
We investigated the efficacy of IKE in vivo in male NCG mice bearing SUDHL6 subcutaneous xenografts. Once tumor volumes reached 100 mm 3 , mice were randomized into five groups and treated with vehicle (5% DMSO in HBSS at pH 4), (C) Tumor volume fold change compared with day 0, measured by electronic caliper daily and calculated using the formula volume = 0.5 3 length 3 width 2 , revealed a reduction of tumor growth by IKE 40 mg/kg (n = 9), IKE 23 mg/kg (n = 11), and IKE NP 23 mg/kg (n = 13) treatment for 14 days compared with vehicle (n = 13) and NP vehicle (n = 13) controls (data analyzed by two-way ANOVA). ns, p > 0.5, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (D) Mouse weight was measured daily and indicated no weight loss upon NP and IKE NP treatments, but weight loss upon IKE 40 mg/kg and IKE 23 mg/kg treatment starting from day 9. Data are plotted as the mean ± SD. ns, not significant. See also Figure S4 .
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unfunctionalized PEG-PLGA NPs in water, 40 mg/kg free IKE (5% DMSO in HBSS at pH 4), 23 mg/kg free IKE (5% DMSO in HBSS at pH 4), or 23 mg/kg IKE NPs (IKE PEG-PLGA NPs in water) via i.p. injection once daily. During the experimental period, mouse weight and tumor volume were measured daily to determine IKE's antitumor effect and possible toxicity. Tumor growth was calculated as the fold change relative to original tumor volume on day 0 before the first dose ( Figure 4C ). Administration of 40 mg/kg IKE, 23 mg/kg IKE, and 23 mg/kg IKE NPs caused a significant decrease in tumor growth starting from day 9 of treatment. The tumor growth inhibition effect was not significantly different between 23 mg/kg free IKE and 23 mg/kg IKE NPs; however, IKE NPs showed less toxicity, as evidenced by weight loss ( Figure 4D ). Compared with saline vehicle, free IKE (5% DMSO in HBSS at pH 4)-treated mice started losing weight from day 9, which might be caused by the precipitation of IKE after administration into the peritoneum, an environment with pH ranges of 7.5-8.0, causing damage to abdominal organs, or possible toxicity of systemic system x c inhibition, or off-target toxicity of IKE. However, IKE NP-treated mice had a similar weight compared with the saline vehicle and the NP vehicle groups; the lower toxicity of the IKE NP formulation might result from the NPs' capability to prevent the aggregation of hydrophobic drugs (Sun et al., 2014) , or the NP EPR effect, which decreases the non-specific distribution and systemic toxicity associated with conventional hydrophobic drugs (Yue et al., 2013) . By analyzing IKE tumor accumulation using liquid chromatography-MS, we found that IKE NPs at 23 mg/kg had slightly enhanced tumor accumulation compared with free IKE at 23 mg/ kg and were comparable to the free IKE 40 mg/kg treatment (Figure S5A) . Overall, the PEG-PLGA NP formulation increased IKE's therapeutic window. Given the fact that PTGS2 mRNA was upregulated upon IKE treatment in vivo ( Figure 3C ), we hypothesized that after IKE treatment, there might be an increased level of the PTGS2 gene product (COX-2) in the tumor. Using immunofluorescence ( Figure 5A ), we found that COX-2 protein expression was indeed increased in IKE-treated tumor tissue ( Figure 5D ). There was no significant COX-2 protein expression increase in IKE NP-treated tumors, which might be due to the slower release of IKE from PEG-PLGA NPs ( Figure S4F ), making the free IKE concentration lower than free IKE-treated tumors. This implies that COX-2 protein abundance is not a highly sensitive pharmacodynamic marker for low concentrations of IKE, but may more effectively report on exposure to high concentrations of IKE.
We further characterized lipid peroxidation in tumor tissues during this efficacy study. Immunofluorescence analysis of tumor tissue from the five groups showed significantly increased dihydropyridine-MDA-lysine adduct levels in IKE-treated and IKE PEG-PLGA NP-treated groups, compared with the saline vehicle and NP vehicle groups ( Figures 5B and 5E ). Compared with saline vehicle, the NP vehicle group had increased levels of dihydropyridine-MDA-lysine adducts, which might be due to low-level ferroptosis induction of ultrasmall (<10 nm in diameter) NPs in the sample, as observed in PEG-coated silica NPs previously . In addition, the thiobarbituric acid-reactive substances (TBARS) assay, which measures the fluorescence of MDA-TBA adducts formed, showed increased MDA levels in tumors in the free IKE and IKE PEG-PLGA NP groups compared with vehicle groups ( Figure 5G ). The TBARS assay is not as sensitive as immunofluorescence for detecting small increases in MDA adducts, suggesting a possible explanation for our inability to detect this increase in the NP vehicle group. Immunofluorescence analysis of 8-OHdG showed increased oxidative DNA damage in IKE-treated and IKE PEG-PLGA NP-treated groups, confirming that IKE treatment induced oxidative damage ( Figures 5C and 5F ). In addition, there was no increase in caspase-3 activity in tumor tissues upon IKE treatment, suggesting that the inhibition of tumor growth was not due to apoptosis, as expected ( Figure S5B ).
DISCUSSION
Recent discoveries have suggested that ferroptosis inducers can have antitumor efficacy (Yu et al., 2017; Gout et al., 2001; Liu et al., 2017) and may synergize with chemotherapy in some cell contexts (Sato et al., 2018; Chen et al., 2015; Yamaguchi et al., 2013; Yu et al., 2015) . However, there is a lack of potent, selective, and metabolically stable tools to study ferroptosis in vivo. Study of the ferroptosis inducer IKE in an SUDHL6 xenograft model demonstrated that IKE and IKE NPs reduce tumor growth by inducing ferroptosis. The IKE PEG-PLGA NP formulation exhibited a larger therapeutic window compared with the free IKE formulation tested. Given the fact that we used a 5% DMSO in HBSS at pH 4 formulation and that IKE is less soluble at pH 7 versus pH 4, we suspect that the toxicity of high-dose free IKE in this study might stem from the precipitation of IKE after injection into the peritoneal cavity.
The induction of ferroptosis theoretically has the potential to shrink tumors. IKE's half-life (T 1/2 ) in plasma and T 1/2 in tumor in SUDHL6 NCG xenograft mice through i.p. injection were 1.83 and 3.50 h, respectively. Compared with the pharmacokinetics of IKE, the once-per-day dosage frequency might be too low to see a tumor shrinking effect; in other words, we might need either a longer half-life compound or formulation or more frequent dosing to balance rapid tumor growth with induction of cell death, to cause tumor regression. The IKE NP formulation had increased accumulation in tumor tissue relative to plasma ( Figure S5A ), but it might not be high enough to counter rapid tumor growth in vivo; delivery of a higher dose to the tumor might be needed. Based on the above considerations, combining IKE with other therapies or designing ferroptosis inducers with enhanced bioavailability and metabolic stability and higher tumor penetration and accumulation is worth investigating to further optimize the therapeutic impact of ferroptosis inducers in diverse cancer models.
Our untargeted lipidomic study identified lipid metabolism features during ferroptosis. First, we observed decreased PEs, PCs, and TAGs upon IKE treatment, possibly resulting from the cleavage of oxidized PUFA tails in PEs, PCs, and TAGs to prevent the oxidative damage to cells induced by IKE treatment. Co-treatment with b-ME, which allows transport of cysteine through systems A, ASC, and L, completely reversed the lipidomic changes caused by IKE treatment. Fer-1 partially prevented the phospholipid decreases in cells, but dramatically increased TAGs. The increased TAG pool might serve as a buffer against lipid peroxidation induced by IKE (Listenberger et al., 2003) . However, the iron chelator DFO did not reverse IKE-induced phospholipid decreases or TAG decreases, indicating that Fenton chemistrymediated lipid peroxidation is not likely a driver of most lipidomic changes during IKE-induced ferroptosis. Second, both the de novo and the remodeling pathways of phospholipids and TAG biosynthesis (Shindou and Shimizu, 2009 ) were activated following IKE treatment. Finally, lipidomic changes following induction of ferroptosis in vivo were characterized here. The data from the tumor samples revealed that DAGs, MAGs, and phospholipids were all significantly increased upon IKE treatment, possibly resulting from the activation of the TAG hydrolysis enzyme, ATGL, and the response of tumor cells to oxidative stress.
In addition, pharmacodynamic markers developed in this study may be beneficial for future ferroptosis efficacy studies. First, the qRT-PCR experiments identified a time-dependent upregulation of numerous genes, including PTGS2, SLC7A11, and CHAC1, following IKE treatment in SUDHL6 cells and in xenograft tumor tissues derived from the same cell line. Second, immunofluorescence experiments showed increased levels of the PTGS2 gene product COX-2, 8-OHdG, and dihydropyridine-MDA-lysine adducts in IKE-treated and IKE PEG-PLGA NP-treated tumors compared with vehicle, with no increased caspase-3 cleavage, a biomarker of apoptosis, in IKE-treated and IKE PEG-PLGA NP-treated tumor tissues. These data (C and F) (C) Immunofluorescence and (F) quantification of 8-OHdG on frozen tumor sections measured by confocal microscopy showed 2.3-, 1.8-, and 2.2-fold increase in 8-OHdG intensity upon IKE NP 23 mg/kg, IKE 23 mg/kg, and IKE 40 mg/kg treatment daily for 14 days. (Sections were cut from five randomly chosen mice in each group, three images from each section were captured on a Zeiss LSM 800 633/1.40 oil DIC objective.) (G) TBARS assay measuring MDA-TBA adduct fluorescence showed 1.6-, 1.4-, and 1.8-fold MDA increase upon IKE NP 23 mg/kg, IKE 23 mg/kg, and IKE 40 mg/kg treatment. ns, p > 0.5, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by one-way ANOVA. Data are plotted as the mean ± SD.
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DLBCL cell lines have differential sensitivity to IKE-induced ferroptosis. The intrinsic factors determining DLBCL ferroptosis sensitivity remain to be explored to increase the understanding of ferroptosis and to enable selection of patients with sensitive tumors. The efficacy of IKE in additional animal cancer models would also be valuable to explore. Moreover, further studies on genes encoding lipid metabolism enzymes identified here would be useful to determine the essentiality of these genes for ferroptosis execution and the contribution of their expression to cell sensitivity to ferroptosis. In summary, we have developed a suitable small molecule and formulation for inhibiting system x c and inducing ferroptosis in mouse tumor models and identified a series of pharmacodynamic markers of ferroptosis. These tools may be beneficial in determining whether there are specific cancer contexts in which ferroptosis induction would be therapeutically beneficial. The lipidomic study performed here may increase our understanding of the roles of lipids in ferroptotic cell death.
SIGNIFICANCE
Emerging evidence has shown the potential antitumor effects of using system x c inhibitors and ferroptosis inducers as single reagents or in combination with chemotherapy in cell culture and some types of xenografts. It is thus important to identify biomarkers and understand the molecular mechanisms of ferroptosis inducers in both tumor cells and cancer models. Here we identify and establish the pharmacokinetic and pharmacodynamic properties of the ferroptosis inducer IKE in a xenograft model, which will be useful for future study of the therapeutic impact of ferroptosis in cancers and other conditions. The work presented here also identified a set of genes that are upregulated by IKE treatment in cell culture and demonstrated that the upregulation of these genes is due to system x c inhibition, as illuminated following co-treatment with ferroptosis inhibitors. The integration of small-molecule tools, untargeted lipidomics, and qRT-PCR provides an efficient means to explore changes in lipid composition and lipid metabolic mechanisms during regulated cell death. Moreover, nanoparticle carriers provide an effective way to improve drug efficacy and reduce systemic toxicity because of targeted localization in tumors. Despite the various nanocarrier systems available and numerous advantages of nanoparticle therapeutics, there are challenges to applying nanocarriers in vivo. One such challenge is to manufacture uniform nanoparticles with high loading capacity at large scale. We utilized a scalable microfluidic platform, which allows for the precise engineering of PEG-PLGA nanoparticles. Given the rapid optimization process and the commercial availability of PEG-PLGA polymers, the nanoparticle system we used here may be useful to other researchers exploring in vivo delivery of ferroptosis inducers.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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We thank Dr. Brandon Fowler of Columbia University for assistance with mass spectrometry for IKE measurement and Hanqing Xiong of Columbia University for assistance with immunofluorescence and pharmacokinetics analysis. This research was supported by the National Cancer Institute (R35CA209896 and P01CA087497 to B.R.S). supernatant was removed and dried on a GeneVac evaporator overnight on an HPLC setting. After drying, the samples were resuspended in 100 mL of methanol and analyzed on the liquid chromatography mass spectrometry (LC-MS), with each sample analyzed twice. Quality control standard samples were prepared by dissolving IKE in 100 mL water and extraction with the same procedures to ensure that the extraction was efficient. LC-MS analysis was performed on a platform comprising a Thermo Scientific Dionex Ultimate 3000RS controlled by Chromeleon (Dionex) and a Bruker amazon SL ESI ion-trap mass spectrometer. Chromatographic separation was performed at 20 C on Agilent Eclipse Plus C18 column (2.1 x 50 mm, 3.5 mm) at 20 C over a 12 minute gradient elution. Mobile phase A consisted of water with 0.1% acetic acid v/v and mobile phase B was methanol with 0.1% acetic acid v/v. After injection, the gradient was held at 80% mobile phase A for 1 min. The gradient was then ramped in a linear fashion to 80% mobile phase over 0.5 min. Over the next 3.5 min, the gradient was ramped in linear fashion to 100% mobile phase B and held at 100% mobile phase B for 3.25 min. The gradient was then ramped in a linear fashion to 80% mobile phase over 0.5 min and held there for the duration of the run. The flow rate was set to 400 mL/min and injection volumes were 5 mL. The retention time for IKE in this gradient was 2.8 min.
AUTHOR CONTRIBUTIONS
Conceptualization
Mass spectrometry analysis was performed on a Bruker Amazon SL (Billerca, MA) in positive ESI mode. Trap Control was used to control the ESI settings with the inlet capillary held at -4500 V and the end plate offset at -500 V. Nitrogen was used as the desolvation gas. Hystar v3.2 was used to integrate the UHPLC and MS applications, and data analysis was performed with the Compass DataAnalysis software. The base peak chromatogram at m/z 655.2 with a width of ± 0.1 was integrated and peak area quantified by standard curve.
Pharmacokinetics (PK) of IKE were assessed using Prism fitted with lognormal of one phase exponential decay. The PK parameters are summarized in Table S1 . Pharmacokinetic and Pharmacodynamic Analysis in NCG Mice Bearing SUDHL6 Xenografts IKE was dissolved in 5% DMSO/95% HBSS at pH 4 to create a 5 mg/mL solution or 3 mg/mL solution. 5% DMSO/95% HBSS at pH 4 was used as vehicle 1. IKE PEG-PLGA nanoparticles and unfunctionalized PEG-PLGA nanoparticles (without IKE) (vehicle 2) prepared with a NanoAssemblr were dialyzed with deionized water overnight, and the water was changed at least twice. Dialyzed IKE-PEG-PLGA nanoparticles and unfunctionalized PEG-PLGA nanoparticles were concentrated by Amicon Ultra-15 Centrifugal Filter Units to create a solution with 80 mg/mL PEG-PLGA nanoparticles. All above solutions were sterilized by filtering through a 0.2 mm syringe filter.
NCG mice 6 weeks of age were injected with 10 million SUDHL-6 cells subcutaneously. Visible tumors appeared after 2 weeks. Tumor size was measured by electronic caliper every 2 days and calculated using the formula: 0.5 x length x width 2 . After another 2 weeks, mice were randomly separated into group of 3 mice per cage with roughly tumor size (1,200 mm 3 ). Mice were dosed at 50 mg/kg IKE using IP at one time and samples were collected at 0, 1, 2, 3, 4, 6, and 24 h with three mice per time point. Mice were dosed with DMSO vehicle by IP and samples were collected at 24 h. Mice were euthanized using a CO 2 gas chamber before xenograft dissection and cardio puncture. Plasma samples were collected and analyzed as described above. Tumors were dissected and divided into 6 segments, frozen on dry ice, and stored at -80 C. Before IKE extraction, tumor tissue samples were thawed at room temperature and weighed. A 2.5-fold ratio of volume of phosphate-buffered saline (PBS) (mL/g) was added to the sample and homogenized using Bead Ruptor 4 at speed 4 for 30 sec. The homogenization step was repeated until the samples were homogenized well (final weight/volume was 0.4 g/mL). 100 mL of homogenized tissue (equal to 40 mg) was added to a new microfuge tube, 900 mL of acetonitrile was added. The samples were mixed for at least 5 minutes by rotating on a shaker and were sonicated for at least 30 sec prior to centrifugation for 10 min at 4,000 x g and 4 C. The supernatant was removed and dried on the GeneVac overnight on the HPLC setting. After drying, the samples were resuspended in 100 mL of methanol and analyzed on the LC-MS with each sample analyzed twice. Technical replicates were averaged. The concentration of IKE in the sample was determined by comparison against a standard curve of IKE in the range of 25 to 2,500 ng/mL. Pharmacodynamic analysis of ferroptosis biomarkers is described in the RT-qPCR, glutathione, immunofluorescence, and lipidomics sections below. Pharmacokinetics parameters of IKE was assessed using Prism fitted with Lognormal of one phase exponential decay. The PK parameters are summarized in Table S2 . IKE Efficacy Study IKE was dissolved in 5% DMSO/95% HBSS at pH 4 to create a 4 mg/mL solution. 5% DMSO/95% HBSS at pH 4 was used as vehicle 1. IKE PEG-PLGA nanoparticles and unfunctionalized PEG-PLGA nanoparticles (without IKE loading) (vehicle 2) prepared with a NanoAssemblr were dialyzed with deionized water overnight; the water was changed at least twice. Dialyzed IKE-PEG-PLGA nanoparticles and unfunctionalized PEG-PLGA nanoparticles were concentrated by Amicon Ultra-15 Centrifugal Filter Units to create a solution with 80 mg/mL PEG-PLGA nanoparticles. All above solutions were sterilized by filter through a 0.2 mm syringe filter.
NCG mice, 6-weeks old, were injected with 10 million SUDHL0-6 cells subcutaneously. The mice were treated after the tumor size reached 100 mm 3 . Mice were separated randomly into treatment groups and dosed with 23 mg/kg IKE, 40 mg/kg IKE, 23 mg/kg IKE PEG-PLGA nanoparticles (equal to 700 mg/kg PEG-PLGA), vehicle 1 (based on volume), and vehicle 2 (700 mg/kg PEG-PLGA) once daily by IP for 14 days. Tumor volume was measured daily with electronic caliper and calculated using the formula: 0.5 x length x width 2 . 3 h after the final dosage, mice were euthanized with CO 2 and tumor tissue was dissected, weighed, divided into 4-6 segments, frozen, and stored at -80 C. Tumor volume change was analyzed in Prism using one-way ANOVA. IKE accumulation in tumor tissues were analyzed using the same method in the above sections. Biomarker characterization in tumor tissues were described in the RT-qPCR, immunofluorescence, TBARS, and lipidomics sections below.
DLBCL Lines Sensitivity Measurement DLBCL cells were plated at 10,000 cells per well in white 384-well plates (32 mL per well) in technical duplicates and incubated overnight. The cells were then treated with 8 mL medium containing a two-fold dilution series of vehicle (DMSO), IKE (starting from 100 mM) with or without Fer-1 (starting from 200 mM). After 24 h incubation, 40 mL of 50% CellTiter-Glo (Promega) 50% cell culture medium was added to each well and incubated at room temperature with shaking for 15 min. Luminescence was measured using a Victor X5 plate reader (PerkinElmer). All cell viability data were normalized to the DMSO vehicle condition. Experiments were performed three independent times with different passages for each cell line. From these data, dose-response curves and IC 50 values were computed using Prism 7.0 (GraphPad).
Flow Cytometry Assay 0.20 million SUDHL-6 cells were seeded in six-well plates and treated with DMSO, IKE, or fer-1 at specific concentration. The final cell density was 0.05 million cells/mL. After 24 h, cells were harvested by centrifuging at 300 x g for 5 min. Cells were resuspended in 500 mL HBSS containing 2 mM C11-BODIPY (BODIPY 581/591 C11) (Thermo Fisher Scientific, D3861) and incubated at 37 C for 15 min. Cells were pelleted and resuspended in HBSS. Fluorescence intensity was measured on the FL1 channel with gating to record live cells only (gate constructed from DMSO treatment group). A minimum of 10,000 cells were analyzed per condition.
Reduced Glutathione Measurement 2.4 million cells were incubated with DMSO, IKE, or b-mercaptoethanol (b-ME) at a density of 0.2 million cells/mL for 24 h. Cells were collected and washed with cold PBS once. Cell number was counted by Vi-Cell. Cells were resuspended in ice-cold RIPA buffer (Thermo Fisher Scientific, 89900) with 100 mL/one million cells. Samples were centrifuged for 15 min at 4 C at 17,000 x g. The resulting supernatant was deproteinized using a trichloroacetic acid and sodium bicarbonate solution and kept on ice. The sample was diluted with assay buffer provided in GSH/GSSG Ratio Detection Assay Kit (Abcam, ab13881) ten-fold. Reduced glutathione (GSH) levels were determined using Fluorometric-Green provided in the kit following the manufacture's protocol. 384-well (Corning) low volume black flat bottom polystyrene non-treated microplates 1230F99 were used.
To perform reduced glutathione measurement in tumor tissue, 10 mg of tumor tissue was mixed with 400 mL RIPA buffer, homogenized at speed 5 for 30 sec using a Bead Ruptor 4 (OMNI International). The sample was centrifuged at 17,000 x g for 5 min, then the above deprotenization and measurement steps performed.
TBARS Assay 10-25 mg tumor tissue was placed into a 1.5 mL Eppendorf microfuge tube, and the sample was placed on dry ice until use. 20 mL/mg ice-cold RIPA buffer with cocktail protease inhibitor (Roche) was added. The tumor tissue was homogenized at speed 5 for 30 sec using Bead Ruptor 4. The sample was centrifuged at 4 C at 1,600 x g for 10 min. The sample was kept on ice and the supernatant used for analysis. Tissue homogenates did not need to be diluted before assaying. TBARS was measured using a TBARS Assay Kit (Cayman 700870), following the manufacture's protocol.
qPCR To perform qPCR analysis in cell culture, DLBCL cells were treated with 0-10 mM IKE, fer-1, or b-ME for the indicated times. RNA was extracted using the Qiashredder and Qiagen RNeasy Mini kits (Qiagen) according to the manufacture's protocol. 2 mg RNA from each sample was reversed transcribed to cDNA using a High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, 4368814) . Quantitative PCR reactions were performed using Power SYBR Green PCR Master Mix (Applied Biosystems) with triplicate measurement on ViiA 7 Real-Time PCR instrument (Thermo Fischer). HPRT1 was used as an internal reference. Differences in mRNA levels compared with HPRT1 were computed between vehicle and experimental groups using the DDCt method. The primers used in the study was listed below.
Genes
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To perform qPCR analysis in mouse tumor tissue, $20 mg of tumor tissue was prepared and kept on dry ice. The frozen tissue was homogenized with Bead Ruptor 4 at speed 4 for 30 sec. The homogenization was repeated once if there remained unhomogenized tissue. Total mRNA was prepared from the cleared homogenate using Ribopure Kit (Thermo Fisher Scientific, am1924). RNA was reverse transcribed to cDNA then used in quantitative PCR experiment following the same steps used in cell qPCR experiment.
Immunofluorescence Study and Quantification
Immunofluorescence Study and Quantification on Cells SUDHL-6 cells were treated with IKE. The cells were harvested by centrifugation and washed with PBS once. The cells were resuspended in PBS, fixed by adding equal volume of 4% paraformaldehyde (PFA), and incubated at room temperature for 15 min. The cells were washed with PBS/0.1% Tween 20 (PBST) twice, resuspended in 10% goat serum (ThermoFisher 50197Z) for 1 h. The cells were incubated with mouse mAb 1F83, which specifically recognizes the malondialdehyde (MDA)-lysine adduct 4-methyl-1,4-dihydropyridine-3,5-dicarbaldehyde (MDHDC) (Yamada et al., 2001) (1:100 dilution) overnight at 4 C. The cells were washed with PBS three times by centrifugation. The cells were incubated with goat anti-mouse IgG H&L (Alexa Fluor 647) (Abcam ab150115) (1:1000) at room temperature for 1 h. The cells were washed with PBST twice by centrifugation, then resuspended in PBS in 24-well plate with poly-lysine-(Sigma Aldrich P4832)-coated cover slips and centrifuged at 1,000 x g for 10 min. ProLong Diamond antifade mountant with DAPI (ThermoFisher P36962) was added to stain the nucleus. All images were captured on a Zeiss LSM 800 confocal microscope at Plan-Apochromat 63x/1.40 Oil DIC objective with constant laser intensity for all samples. When applicable, line-scan analysis was performed on representative confocal microscopy images using Zeiss LSM software to qualitatively visualize fluorescence overlap. The intensity above threshold of the fluorescent signal of the bound antibodies was analyzed using NIH ImageJ software. Data were expressed as fold change compared with the vehicle. Immunofluorescence Study and Quantification on Frozen Tissue Sections Tumor tissues were fixed in 4% paraformaldehyde (PFA) for 24h at 4 C followed by washing with PBS three times. The tissues were perfused in 30% sucrose for 24h at 4 C for cryo-protection. The samples were embedded in OCT cryostat sectioning medium, and then moved directly into a cryostat. After equilibration of temperature, frozen tumor tissues were cut into 5 mm thick sections. Tissue sections were mounted on to poly-L-lysine coated slides by placing the cold sections onto warm slides. Slides were stored at -80 C until staining. For staining, slides were warmed to room temperature followed by washing with PBS twice. A hydrophobic barrier pen was used to draw a circle on each slide. The slides were permeabilized with PBS/0.4% Triton X-100 twice before non-specific-binding blocking by incubating the sections with 10% goat serum (ThermoFisher 50197Z) for 30 minutes at room temperature. The sections were separately incubated with mouse anti-MDA mAb 1F83 (1:1000 dilution), anti-cyclooxygenase 2 (COX 2, AKA PTGS2) antibody (Abcam, ab15191, 1:200 dilution), or anti-8-OH-dG (DNA/RNA damage) antibody (Abcam, ab62623, 1:200 dilution) overnight at 4 C in humidified chambers. Sections were washed with PBST for twice before incubating with goat anti-mouse IgG H&L (Alexa Fluor 647) (Abcam, ab150115, 1:1000 dilution) or goat anti-rabbit IgG H&L highly cross-absorbed secondary antibody (Alexa Fluor488, Thermo Fisher Scientific, A-11034, 1:1000) at room temperature for 1 h. Slides were then washed twice with PBST. ProLong Diamond antifade mountant with DAPI (ThermoFisher P36962) was added onto slides, which were then covered with the coverslips, sealed by clear fingernail polish and observed under confocal microscopy. All images were captured on a Zeiss LSM 800 confocal microscope at Plan-Apochromat 63x/1.40 Oil DIC objective with constant laser intensity for all analyzed samples. The intensity above threshold of the fluorescent signal of the bound antibodies was analyzed using NIH ImageJ software. Data were expressed as fold change comparing with the vehicle. Immunofluorescence Study and Quantification on Paraffin-Embedded Tissue Sections Tumor tissue was fixed in 4% paraformaldehyde (PFA) for 24 h at 4 C followed by washing three times with PBS. The samples were fixed in paraffin. Six series of 5 mM sections were obtained with a sliding microtome. The serial sections were then mounted on gelatin-coated slide. The paraffin-embedded tissue sections were deparaffinized with xylene three times, 5 min each, followed by rehydrating in 100%, 90%, 70%, and 50% ethanol, two washes 5 min each, then rinsed with distilled water. Antigen retrieval was performed in Tris-EDTA buffer, pH 9.0, 95-100 C for 10 min. Then sections were rinsed in PBST, 2 min each. Then the above steps were followed for staining and quantification.
Continued
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Western Blot 10-25 mg tumor tissue was placed into a 1.5 mL Eppendorf microfuge tube, and the sample was placed on dry ice until use. 20 mL/mg ice cold RIPA buffer with cocktail protease inhibitor (Roche) was added. The tumor tissue was homogenized at speed 5 for 30 sec using Bead Ruptor 4. The sample was centrifuged at 4 C at 1,600 x g for 10 min. The sample was kept on ice and the supernatant used for analysis. Caspase-3 antibody which could recognize both full-length caspase-3 and cleaved caspae-3 was used. a-tubulin antibody was used as the reference.
Nanoparticle Formulation and Characterization
Formulation (Poly(ethylene glycol) methyl ether-block-poly(lactide-co-glycolide) (PEG-PLGA) with PEG average M n 5,000, PLGA M n 15,000, and lactide:glycolide 50:50 was purchased from Sigma-Aldrich (900948). PEG-PLGA nanoparticles were prepared using a microfluidic mixer with the NanoAssemblr Benchtop instrument (Precision NanoSystems Inc., Vancouver, BC) by mixing oil and aqueous phases. PEG-PLGA was dissolved in 25% acetone/75% DMSO at concentration of 10 mg/mL. Milli-Q water was used as aqueous phase. For synthesis of PEG-PLGA nanoparticles, two phases were injected through two inlets of the microfluidic mixer with a speed of 8 mL/min and a volume ratio of 1:1. Nanoparticles were collected in the sample collection tube by discarding an initial and final waste volume of 0.25 and 0.05 mL. Samples were dialyzed in at least 500 x deionized water overnight using 10 kD cut-off dialysis bag (ThermoFisher, SnakeSkin Dialysis Tubulin, 68100) and the water was changed twice in between to remove organic solvent. Then the purified nanoparticles were concentrated by centrifuging using Amicon Ultra-15 Centrifugal Filter Units (Millipore, UF9050) at 2,168 x g to the desired concentration. For encapsulation of IKE, IKE was dissolved in a solution of PEG-PLGA in 25% acetone and 75% DMSO. The final concentration of PEG-PLGA was 10 mg/mL and IKE was 1.5 mg/mL. The process was the same with PEG-PLGA nanoparticles preparation. Nanoparticle size and potential were measured using a Malvern Zetasizer Nano ZS. IKE Quantification in PEG-PLGA Nanoparticles IKE concentration was determined in PEG-PLGA nanoparticles using Liquid Chromatography-Mass Spectrometry (LC -MS). IKE was extracted from nanoparticles by mixing 100 mL of samples with 900 mL of acetonitrile. After mixing for 1 h, the mixture was sonicated for 5 min and then centrifuged at 4000 rpm for 10 min. The supernatant was transferred to a new vial. The organic solvent was removed by Genevac evaporation. The residues were re-dissolved in 100 mL MeOH in a LC-MS vial. Calibration standards and quality control samples were prepared spanning a range of 25 ng/ml to 1250 ng/ml IKE in MeOH. Peak integration and data analysis were performed. Using the standard curve, IKE concentration in the sample was determined. Measurement of IKE PEG-PLGA Cellular Activity DLBCL cells or HT-1080 cells were plated at 2,000 cells per well in white 384-well plates (32 mL per well) in technical duplicates and incubated overnight. The cells were then treated with 8 mL medium containing a two-fold dilution series of vehicle 1 (DMSO), IKE, fer-1, vehicle 2 (unfunctional PEG-PLGA nanoparticles), or IKE PEG-PLGA nanoparticles. The final concentration of IKE in PEG-PLGA nanoparticles was measured by LC-MS as described in the sections below. After 24 h incubation with compounds, 40 mL of 50% CellTiter-Glo (Promega) 50% cell culture medium was added to each well and incubated at room temperature with shaking for 15 min. Luminescence was measured using a Victor X5 plate reader (PerkinElmer). All cell viability data were normalized to the DMSO vehicle condition. Experiments were performed in three independent times with different passages for each cell line. From these data, dose-response curves and IC 50 values were computed using Prism 7.0 (GraphPad). Kinetics of IKE Release from PEG-PLGA Nanoparticles 200 mL newly generated IKE PEG-PLGA nanoparticles were mixed with 800 mL PBS solution. They were incubated on a shaker at 37 C. Samples were collected followed by centrifugation at 10,000 x g for 10 min. The obtained supernatant was evaporated using a GeneVac. The obtained residues were resuspended in 100 mL methanol and analyzed with LC-MS with the methods described above. Peak integration and data analysis were performed to quantify released IKE concentration in the samples.
Solubility Measurements
Solubility measurement samples were prepared in a 96-well Corning Costar plate with two at 1% and 5% DMSO v/v with a total sample volume of 200 mL in MilliQ water. A BMG Labtech NEPHELOstar nephelometer was used to measure turbidity of the samples with the following parameters per the instrument manufacturer: Gain = 80, Laser Focus= 2.50 mm, and Laser Intensity = 90%. Samples were shaken in the nephelometer by orbital shaking for 3s prior to the turbidity measurement. Sample values were blanked in the instrument software using the corresponding water and DMSO condition values. Turbidity 4000 NTU Calibration Standard-Formazin (Millipore-Sigma) was used as a positive control for all turbidity measurements. The turbidity of each sample was measured within 20 minutes of initial preparation. After the initial measurement, the sample plates were covered with aluminum sealing film and allowed to sit overnight at room temperature prior to re-measuring.
IKE Synthesis
IKE was synthesized using methods previously reported (Larraufie et al., 2015) except that the reduction step of nitrobenzene to aniline was modified, which is described here. To a solution of substituted nitrobenzene (1 equiv.) in MeOH (0.1 M), Pd/C (0.2 equiv.) were added. The reaction mixture was gas exchanged with hydrogen, then stirred at room temperature overnight under 1 atm hydrogen gas. Upon completion, the mixture was filtered with celite and concentrated under vacuo. The resulting mixture was purified by combiflash 0-10% methanol/dichloromethane to afford the corresponding aniline. 7.83 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 1H), 7.69 (s, 1H), 7.54 (ddd, J = 8.2, 7.0, 1.3 Hz, 1H), 2H), 2H), 6.98 (s, 1H), 2H), 5.48 (d, J = 17.6 Hz, 1H), 5.36 (d, J = 17.6 Hz, 1H), 5.32 (s, 2H), 1H) Mass Spectrometry-Based Untargeted Lipidomics Sample Preparation In Vitro Study Lipids were extracted from each sample as described below. 5 million cells treated with DMSO, 1 mM IKE, 500 nM IKE with or without 10 mM fer-1 and 10 mM b-Me for 24 hours were homogenized in 250 mL cold methanol containing 0.1% butylated hydroxyl toluene (BHT) with micro tip sonicator. Homogenized samples were transferred to fresh glass tubes containing 850 mL of cold methyl-tertbutyl ether (MTBE) and vortex-mixed for 30 sec. To enhance extraction efficiency of lipids, the samples were incubated overnight at 4 C on the shaker. On the next day, 200 mL of cold water was added to each sample, and incubated for 20 min on ice before centrifugation at 3,000 rpm for 20 min at 4 C. The organic layer was collected followed by drying under a gentle stream of nitrogen gas on ice and stored at -80 C until LC-MS analysis. The protein pellet was used to measure protein concentration using Bio-Rad protein assay. The samples were re-constituted in a solution containing IPA/ ACN /water (4:3:1, v/v/v) containing mixture of internal standard for further MS analysis. A quality control (QC) sample was prepared by combining 40 mL of each sample to assess the reproducibility of the features through the runs. Ultra-High Performance Liquid Chromatography Analysis Chromatographic separation of extracted lipids was carried out at 55 C on Acquity UPLC HSS T3 column (2.13 150 mm, 1.8 mm) over a 17-min gradient elution. Mobile phase A consisted of ACN/water (60:40, v/v) and mobile phase B was IPA/ACN/water (85:10:5, v/v/v) both containing 10 mM ammonium acetate and 0.1% acetic acid. After injection, the gradient was held at 60% mobile phase A for 1.5 min. For the next 12 min, the gradient was ramped in a linear fashion to 100% B and held at this composition for 3 min. The eluent composition returned to the initial condition in 1 min, and the column was re-equilibrated for an additional 1 min before the next injection was conducted. The flow rate was set to 400 mL/min and Injection volumes were 5 mL using the flow-through needle mode in both positive and negative ionization modes. The QC sample was injected between the samples and at the end of the run to monitor the performance and the stability of the MS platform. This QC sample was also injected at least 5 times at the beginning of the UPLC/MS run, in order to condition the column.
Mass Spectrometry Analysis
The Synapt G2 mass spectrometer (Waters, Manchester, U.K.) was operated in both positive and negative electrospray ionization (ESI) modes. For positive mode, a capillary voltage and sampling cone voltage of 3 kV and 32 V were used. The source and desolvation temperature were kept at 120 C and 500 C, respectively. Nitrogen was used as desolvation gas with a flow rate of 900 L/hr. For negative mode, a capillary voltage of -2 kV and a cone voltage of 30 V were used. The source temperature was 120 C, and desolvation gas flow was set to 900 L/hr. Dependent on the ionization mode the protonated molecular ion of leucine encephalin ([M+H] + , m/z 556.2771) or the deprotonated molecular ion ([M-H] -, m/z 554.2615) was used as a lock mass for mass accuracy and reproducibility. Leucine enkephalin was introduced to the lock mass at a concentration of 2 ng/mL (50% ACN containing 0.1% formic acid), and a flow rate of 10 mL/min. The data was collected in duplicates in the centroid data independent (MS E ) mode over the mass range m/z 50 to 1600 Da with an acquisition time of 0.1 seconds per scan.
The QC samples were also acquired in enhanced data independent ion mobility (IMS-MS E ) in both positive and negative modes for enhancing the structural assignment of lipid species. The ESI source settings were the same as described above. The traveling wave velocity was set to 650 m/s and wave height was 40 V. The helium gas flow in the helium cell region of the ion-mobility spectrometry (IMS) cell was set to 180 mL/min to reduce the internal energy of the ions and minimize fragmentation. Nitrogen as the drift gas was held at a flow rate of 90 mL/min in the IMS cell. The low collision energy was set to 4 eV, and high collision energy was ramping from 25 to 65 eV in the transfer region of the T-Wave device to induce fragmentation of mobility-separated precursor ions. Data Pre-processing and Statistical Analysis All raw data files were converted to netCDF format using DataBridge tool implemented in MassLynx software (Waters, version 4.1). Then, they were subjected to peak-picking, retention time alignment, and grouping using XCMS package (version 3.2.0) in R (version 3.5.1) environment. For the peak picking, the CentWave algorithm was used with the peak width window of 2-25 s. For peak grouping, bandwidth and m/z-width of 2 s and 0.01 Da were used, respectively. After retention time alignment and filling missing peaks, an output data frame was generated containing the list of time-aligned detected features (m/z and retention time) and the relative signal intensity (area of the chromatographic peak) in each sample. Technical variations such as noise were assessed and removed from extracted features' list based on the ratios of average relative signal intensities of the blanks to QC samples (blank/ QC >1.5). Also, peaks with variations larger than 30% in QCs were eliminated. Multivariate and univariate analyses were performed using (version 4.0) and in R (version 3.5.1) environment. Group differences were calculated using VIP scores of PLS-DA model and one-way ANOVA (p < 0.05) and false discovery rate of 5% to control for multiple comparisons. figure. (B) . RT-qPCR analysis of gene expression related to lipids biosynthesis and peroxidation in tumor tissue samples from one dosage of IKE treatment comparing with vehicle treatment. (C) Dose-response curves of SUDHL-6 cells was determined by adding free fatty acids in a 10-point, two-fold dilution series for 24 hours, followed by a Cell Titor-Glo luminescent cell viability test. γ-l-linolenic acid, eicosapentaenoic acid, and arachidonic acid are toxic to cells at high concentration. (D) Dose-response curves of SUDHL-6 cells was determined by treating with IKE in a 10-point, twofold dilution series in the presence of DMSO or 10 μM free fatty acids.
Relative Area Under Curve (AUC) to DMSO cotreatment was used to indicate the sensitization or protection effect of free fatty acids to IKE-induced ferroptosis. Figure 4 and results section. (A) At a flow rate of 8 mL/min and PEG-PLGA polymer concentration of 10 mg/mL in DMSO, with aqueous: organic (water: DMSO) ratio increases, the average diameter of PEG-PLGA nanoparticles formulated by NanoAssemblr increased. (B) At a flow rate of 8 mL/min, PEG-PLGA polymer concentration of 10 mg/mL, and aqueous: organic ratio of 1: 1, IKE PEG-PLGA NP prepared from 25% acetone/DMSO has relatively smaller IC50 comparing with 0% acetone/DMSO and 50% acetone/DMSO, indicating higher IKE encapsulation rate in 25% acetone/DMSO. All three solvents produced IKE PEG-PLGA NP with size smaller than 100 nm and polydispersity index (PDI) around 0.2. (C) After concentration using filter units with concentration factors up to 20, PEG-PLGA NP's average diameter and PDI weren't significantly increased. (D) Upon different initial IKE loading in PEG-PLGA NP formulation, 15 wt% IKE showed the highest potency and was used in the following experiments. E) With condition of 10 mg/mL PEG-PLGA polymer and 1.5 mg/mL IKE dissolved in 25% acetone/DM-SO organic phase and mixed with water phase at flow rate of 8 mL/min followed by purification with dialysis and concentration with centrifugation, IKE PEG-PLGA NP has average diameter of 82.49 nm and PDI 0.174. (F) IKE release rate measured by LC-MS showed controlled release of IKE from PEG-PLGA NP. (G) IKE and IKE PEG-PLGA NP-induced DLBCL cell death was rescued by co-treatment with Fer-1. The cell viability was measured by co-treating cells with a two-fold series dilution of IKE (starting from 10 μM) and two-fold series dilution of Fer-1 (starting from 10 μM) for 24 hours followed by a Cell Titor-Glo luminescent cell viability test. The x-axis shows the concentration of both IKE and Fer-1. Data are plotted as the mean ± s.d., n=2 biologically replicates. Three independent experiments were performed with similar results.
